5 stories mentioning ARWRUpdated just now
Every FINWIRES story that references ARWR, newest first.
Arrowhead Pharmaceuticals (ARWR) said Monday the European Commission has granted marketing authorization for Redemplo as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome.The approval was supported by positive phase 3 Palisade trial data, the company said.Shares were up over 1% in afternoon trading.Price: $82.98, Change: $+1.16, Percent Change: +1.42%
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $85.09, according to analysts polled by FactSet.Price: $73.94, Change: $-4.01, Percent Change: -5.14%
Arrowhead Pharmaceuticals (ARWR) said Tuesday it has signed an agreement with Madrigal Pharmaceuticals (MDGL) to exclusively license its ARO-PNPLA3 program, which is evaluating a potential treatment for metabolic dysfunction-associated steatohepatitis, or MASH.Under the agreement, Arrowhead said that Madrigal will receive a global license to develop, manufacture, and commercialize ARO-PNPLA3, which uses the TRiM platform to silence hepatocyte expression of patatin-like phospholipase domain-containing 3, or PNPLA3, as a potential treatment for patients with MASH.When the deal closes, Arrowhead said it will receive a $25 million upfront payment and be eligible to receive up to an additional $975 million upon meeting development, regulatory, and sales milestones.Arrowhead said it is also eligible to receive tiered royalties on commercial sales ranging from high single digits to the mid-teens.Price: $76.58, Change: $+0.19, Percent Change: +0.25%
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $85.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Arrowhead Pharmaceuticals (ARWR) has an average rating of Buy and mean price target of $84.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
